Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?Zacks Investment Research • 05/14/26
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026GlobeNewsWire • 05/13/26
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated personsGlobeNewsWire • 05/12/26
Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weightCNBC • 05/12/26
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on ObesityGlobeNewsWire • 05/12/26
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on ObesityGlobeNewsWire • 05/12/26
Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelinesProactive Investors • 05/11/26
Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapyReuters • 05/11/26
Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 marketProactive Investors • 05/08/26
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo NordiskCNBC • 05/07/26
Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.WSJ • 05/07/26